Get the Stockscreener App
131.58
2.70%
-3.65
After Hours:
131.58
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Ligand Pharmaceuticals Inc stock is traded at $131.58, with a volume of 227.71K.
It is down -2.70% in the last 24 hours and up +15.75% over the past month.
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.
See More
Previous Close:
$135.23
Open:
$133.72
24h Volume:
227.71K
Relative Volume:
1.60
Market Cap:
$2.54B
Revenue:
$152.42M
Net Income/Loss:
$45.24M
P/E Ratio:
52.42
EPS:
2.51
Net Cash Flow:
$6.97M
1W Performance:
-0.94%
1M Performance:
+15.75%
6M Performance:
+12.90%
1Y Performance:
+20.73%
1-Day Range:
$131.12
$137.25
1-Week Range:
$131.12
$138.02
52-Week Range:
$90.29
$143.13
Ligand Pharmaceuticals Inc Stock (LGND) Company Profile
Name
Ligand Pharmaceuticals Inc
Sector
Industry
Phone
858-550-7500
Address
3911 SORRENTO VALLEY BLVD, SAN DIEGO, CA
Compare LGND with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LGND
Ligand Pharmaceuticals Inc
|
131.58 | 2.61B | 152.42M | 45.24M | 6.97M | 2.51 |
|
VRTX
Vertex Pharmaceuticals Inc
|
456.87 | 120.48B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.46 | 59.88B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
392.24 | 44.31B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
670.33 | 36.65B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
301.13 | 32.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Ligand Pharmaceuticals Inc Stock (LGND) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-10-25 | Initiated | Stifel | Buy |
| Oct-03-24 | Initiated | Oppenheimer | Outperform |
| Jul-30-24 | Initiated | RBC Capital Mkts | Outperform |
| Apr-14-21 | Resumed | Stephens | Overweight |
| Feb-04-21 | Reiterated | H.C. Wainwright | Buy |
| Oct-06-20 | Initiated | Barclays | Overweight |
| Mar-24-20 | Downgrade | Argus | Buy → Hold |
| Mar-10-20 | Initiated | Guggenheim | Neutral |
| Feb-06-20 | Initiated | The Benchmark Company | Buy |
| Sep-19-19 | Upgrade | Barclays | Equal Weight → Overweight |
| Jun-11-19 | Initiated | Barclays | Equal Weight |
| May-03-19 | Reiterated | H.C. Wainwright | Buy |
| Mar-06-19 | Reiterated | H.C. Wainwright | Buy |
| Oct-29-18 | Upgrade | ROTH Capital | Neutral → Buy |
| Oct-02-18 | Reiterated | H.C. Wainwright | Buy |
| Sep-11-18 | Reiterated | Argus | Buy |
| Aug-17-18 | Initiated | Goldman | Neutral |
| Aug-08-18 | Downgrade | ROTH Capital | Buy → Neutral |
| Jun-21-18 | Initiated | Argus | Buy |
| Dec-27-17 | Reiterated | H.C. Wainwright | Buy |
| Sep-05-17 | Resumed | H.C. Wainwright | Buy |
| Oct-05-16 | Reiterated | H.C. Wainwright | Buy |
| Aug-05-16 | Downgrade | Deutsche Bank | Hold → Sell |
| Mar-11-16 | Initiated | Sidoti | Buy |
| Mar-03-16 | Initiated | H.C. Wainwright | Buy |
View All
Ligand Pharmaceuticals Inc Stock (LGND) Latest News
Orchestra BioMed secures $70 million from Ligand and Medtronic - Investing.com
Ligand and Medtronic Commit $70 Million in Strategic Capital to Orchestra BioMed - GlobeNewswire
$70M Strategic Investment Powers Orchestra BioMed's Revolutionary Leadless Pacemaker Technology - Stock Titan
How Ligand Pharmaceuticals Incorporated stock performs during market volatilityTrend Analysis for Safer Trades Gains Popularity - beatles.ru
When is Ligand Pharmaceuticals Incorporated stock expected to show significant growthFinancial News Report That Work - jammulinksnews.com
Oppenheimer raises Ligand Pharma stock price target to $162 on royalty growth - Investing.com Australia
Oppenheimer raises Ligand Pharma stock price target to $162 on royalty growth By Investing.com - Investing.com South Africa
Key External Factors That Drive Ligand Pharmaceuticals Incorporated Stock Price MovementsLow Risk Equity Screener With Results Shared - metal.it
What makes Ligand Pharmaceuticals Incorporated stock price move sharplyWeekly Hot Picks With Buy Confidence Released - metal.it
Ligand Pharmaceuticals Incorporated Recovery Likely Here’s What Data ShowsAI Powered High Return Stock Calls Dominate Watchlists - metal.it
Published on: 2025-07-29 17:16:20 - metal.it
EQUITY NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit against Ligand Pharmaceuticals Incorporated and Encourages Investors with Losses to Contact the Firm - ACCESS Newswire
Why Ligand Pharmaceuticals Incorporated stock attracts strong analyst attentionDaily Stock Market Swing Alerts Highlight Key Movers - metal.it
Published on: 2025-07-29 03:23:14 - metal.it
What are Ligand Pharmaceuticals Incorporated company’s key revenue driversUnprecedented profits - jammulinksnews.com
What is the risk reward ratio of investing in Ligand Pharmaceuticals Incorporated stockAchieve breakthrough investment performance - jammulinksnews.com
How does Ligand Pharmaceuticals Incorporated compare to its industry peersAchieve breakthrough profits with expert advice - jammulinksnews.com
Is Ligand Pharmaceuticals Incorporated stock overvalued or undervaluedHigh-performance investment picks - jammulinksnews.com
Is Ligand Pharmaceuticals Incorporated stock a growth or value playPrecision Entry Strategy - metal.it
Why is Ligand Pharmaceuticals Incorporated stock attracting strong analyst attentionMarket-beating returns - jammulinksnews.com
Ligand Pharmaceuticals Incorporated Company Revenue and Profit Trends: A Deep Dive10x Potential Stocks - metal.it
Ligand Pharmaceuticals Incorporated Stock Analysis and ForecastHigh-margin investment plays - PrintWeekIndia
What analysts say about Ligand Pharmaceuticals Incorporated stockFree Capital Growth Strategies - PrintWeekIndia
What drives Ligand Pharmaceuticals Incorporated stock priceBreakout portfolio performance - Autocar Professional
Ligand to Report Second Quarter 2025 Financial Results on August 7, 2025 - Yahoo Finance
Is Ligand Pharmaceuticals Incorporated a good long term investmentHigh-velocity capital appreciation - jammulinksnews.com
Analysts Offer Insights on Healthcare Companies: Ligand Pharma (LGND) and Sarepta Therapeutics (SRPT) - The Globe and Mail
Stifel reiterates Buy rating on Ligand Pharma stock at $143 price target - Investing.com Canada
Teacher Retirement System of Texas Has $534,000 Holdings in Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) - Defense World
Ligand Pharmaceuticals stock hits 52-week high at 130.0 USD - Investing.com Australia
Ligand Pharmaceuticals stock hits 52-week high at 130.0 USD By Investing.com - Investing.com Nigeria
Ligand Pharmaceuticals Inc Stock (LGND) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.43%
2.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):